Media Coverage

Transforming raw data into actionable information is crucial to the financial future of provider organizations, especially as pressure builds on providers to align their care delivery approach with value-based care and consumerism in healthcare. However, many providers lack the time and money to implement this critical function. Fortunately, the right technology can assist providers in getting the most out of their data while freeing up resources better used for patient care. A 2018 Quest Diagnostics survey of physicians and health plan executives found that providers do not have access to the tools they need to succeed under value-based arrangements. Providers still need EHRs, clinical decision support, data analytics, and EHR plug-ins or modules, as well as access to comprehensive patient data.

The American Diabetes Association (the Association) recently released a new economic report that details the fiscal impact of diabetes in the United States – and the results should alarm employers, benefit managers, and HR executives. According to the Association, about 30.3 million people in the U.S. are living with diabetes. In 2017, the total estimated costs associated with diagnosed diabetes were a staggering $327 billion, an increase of 26 percent compared to 2012. About one-third of this cost -- $109 billion -- is due to medical costs to care for patients with diabetes. Another $30 billion is due to indirect costs in the employed population, including increased absenteeism and reduced productivity.

A growing number of employers are adopting workplace wellness programs to improve employee health and subsequently lower their health insurance spend. As they do, benefit managers are tasked with vetting options that will deliver meaningful health and financial results for their companies.A study published in the peer-reviewed journal PLoS ONE, for instance, found that one in three first-time participants in a company-sponsored, lab-based wellness program by Quest Diagnostics were not aware they were at risk for a serious medical condition, such as diabetes or heart disease, according to biometric screening results.

Quest Diagnostics announced today that it will provide full laboratory management services for Georgia-based Houston Medical Center and Perry Hospital. Under the agreement, Quest will provide management expertise, lab equipment, supplies, and procurement processes to the two hospitals. It will also perform reference testing to them. Other terms of the deal were not disclosed.

Quest Diagnostics, the world`s leading provider of diagnostic information services, today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company`s Board has 11 members.

Quest Diagnostics Inc. this week named a chief information and digital officer, combining two enterprise technology roles, as digital tools continue to expand beyond providing back-room business support and into strategic data management and analytics. Gabrielle Wolfson, a former Xerox Corp. chief information officer, took on the dual role earlier this month at the medical diagnostic-information provider known for blood work, urinalysis and other laboratory tests, a company spokesperson said.

Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction. Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest clients in Missouri and a preferred pathology provider in the greater Midwestern region. The professional services agreement will go into effect at the time the acquisition is completed, which is expected in the first quarter of 2019.

Quest Diagnostics named Gabrielle Wolfson, a veteran IT business leader, as the company's new senior vice president and chief information and digital officer.

Quest Diagnostics saw fourth-quarter 2018 revenues of $1.84 billion and net income of $127 million. The company should grow by 2% this year, driven by acquisitions, said CEO Steve Rusckowski.

As fentanyl comes and goes in the news, it still remains a serious drug in America. Fentanyl is highly addictive synthetic opioid 50 to 100 times more potent than morphine and 50 times more potent than many forms of heroin. The pharmaceutical drug is manufactured for pain management; however clandestine laboratories also produce the drug and mix in heroin. Sometimes referred to as Apace, China Girl, Dance Fever, or He-Man, the deadly cocktail has infiltrated our streets, neighborhoods, and workplaces.